Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran

Mehdi Mirsaeidi, Payam Tabarsi, Kaveh Khoshnood, Majid Valiollah Pooramiri, Ali Rowhani-Rahbar, Seyed Davood Mansoori, Heydar Masjedi, Soheyla Zahirifard, Foroozan Mohammadi, Parisa Farnia, Mohammad Reza Masjedi, Ali Akbar Velayati

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Setting: Masih Daneshvari Hospital, Tehran, Iran, 2000-2002. Objective: To evaluate the effectiveness of multiple drug-resistant tuberculosis (MDR-TB) treatment for the first time in Iran. Design: All cases of MDR-TB with complete follow-up data were recruited and results of their treatments were evaluated. Results: MDR-TB treatment was initiated with 5.23 drugs, on average. Isoniazid, amikacin, and ofloxacin were present in the drug regimen of all patients. Average duration of the treatment was 18.5 months (range, 7-36). Over 76% of the patients responded to the treatment (negative smear and culture). Cure and probable cure were documented in seven (41.2%) and four (23.5%) of the patients, respectively. No failure in the treatment occurred when cycloserine was present in the treatment regimen. Conclusion: A majority of the MDR-TB patients in Iran can be cured with the use of appropriate treatment regimens. An even greater success could be achieved by providing more second-line drugs.

Original languageEnglish (US)
Pages (from-to)317-322
Number of pages6
JournalInternational Journal of Infectious Diseases
Volume9
Issue number6
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Multidrug-Resistant Tuberculosis
Iran
Therapeutics
Pharmaceutical Preparations
Cycloserine
Ofloxacin
Amikacin
Isoniazid
Treatment Failure

Keywords

  • Iran
  • Multiple drug-resistant tuberculosis
  • Treatment

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Mirsaeidi, M., Tabarsi, P., Khoshnood, K., Pooramiri, M. V., Rowhani-Rahbar, A., Mansoori, S. D., ... Velayati, A. A. (2005). Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. International Journal of Infectious Diseases, 9(6), 317-322. https://doi.org/10.1016/j.ijid.2004.09.012

Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. / Mirsaeidi, Mehdi; Tabarsi, Payam; Khoshnood, Kaveh; Pooramiri, Majid Valiollah; Rowhani-Rahbar, Ali; Mansoori, Seyed Davood; Masjedi, Heydar; Zahirifard, Soheyla; Mohammadi, Foroozan; Farnia, Parisa; Masjedi, Mohammad Reza; Velayati, Ali Akbar.

In: International Journal of Infectious Diseases, Vol. 9, No. 6, 11.2005, p. 317-322.

Research output: Contribution to journalArticle

Mirsaeidi, M, Tabarsi, P, Khoshnood, K, Pooramiri, MV, Rowhani-Rahbar, A, Mansoori, SD, Masjedi, H, Zahirifard, S, Mohammadi, F, Farnia, P, Masjedi, MR & Velayati, AA 2005, 'Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran', International Journal of Infectious Diseases, vol. 9, no. 6, pp. 317-322. https://doi.org/10.1016/j.ijid.2004.09.012
Mirsaeidi, Mehdi ; Tabarsi, Payam ; Khoshnood, Kaveh ; Pooramiri, Majid Valiollah ; Rowhani-Rahbar, Ali ; Mansoori, Seyed Davood ; Masjedi, Heydar ; Zahirifard, Soheyla ; Mohammadi, Foroozan ; Farnia, Parisa ; Masjedi, Mohammad Reza ; Velayati, Ali Akbar. / Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. In: International Journal of Infectious Diseases. 2005 ; Vol. 9, No. 6. pp. 317-322.
@article{b3a861c24f2749a4b6cfa3116cffdd59,
title = "Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran",
abstract = "Setting: Masih Daneshvari Hospital, Tehran, Iran, 2000-2002. Objective: To evaluate the effectiveness of multiple drug-resistant tuberculosis (MDR-TB) treatment for the first time in Iran. Design: All cases of MDR-TB with complete follow-up data were recruited and results of their treatments were evaluated. Results: MDR-TB treatment was initiated with 5.23 drugs, on average. Isoniazid, amikacin, and ofloxacin were present in the drug regimen of all patients. Average duration of the treatment was 18.5 months (range, 7-36). Over 76{\%} of the patients responded to the treatment (negative smear and culture). Cure and probable cure were documented in seven (41.2{\%}) and four (23.5{\%}) of the patients, respectively. No failure in the treatment occurred when cycloserine was present in the treatment regimen. Conclusion: A majority of the MDR-TB patients in Iran can be cured with the use of appropriate treatment regimens. An even greater success could be achieved by providing more second-line drugs.",
keywords = "Iran, Multiple drug-resistant tuberculosis, Treatment",
author = "Mehdi Mirsaeidi and Payam Tabarsi and Kaveh Khoshnood and Pooramiri, {Majid Valiollah} and Ali Rowhani-Rahbar and Mansoori, {Seyed Davood} and Heydar Masjedi and Soheyla Zahirifard and Foroozan Mohammadi and Parisa Farnia and Masjedi, {Mohammad Reza} and Velayati, {Ali Akbar}",
year = "2005",
month = "11",
doi = "10.1016/j.ijid.2004.09.012",
language = "English (US)",
volume = "9",
pages = "317--322",
journal = "International Journal of Infectious Diseases",
issn = "1201-9712",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran

AU - Mirsaeidi, Mehdi

AU - Tabarsi, Payam

AU - Khoshnood, Kaveh

AU - Pooramiri, Majid Valiollah

AU - Rowhani-Rahbar, Ali

AU - Mansoori, Seyed Davood

AU - Masjedi, Heydar

AU - Zahirifard, Soheyla

AU - Mohammadi, Foroozan

AU - Farnia, Parisa

AU - Masjedi, Mohammad Reza

AU - Velayati, Ali Akbar

PY - 2005/11

Y1 - 2005/11

N2 - Setting: Masih Daneshvari Hospital, Tehran, Iran, 2000-2002. Objective: To evaluate the effectiveness of multiple drug-resistant tuberculosis (MDR-TB) treatment for the first time in Iran. Design: All cases of MDR-TB with complete follow-up data were recruited and results of their treatments were evaluated. Results: MDR-TB treatment was initiated with 5.23 drugs, on average. Isoniazid, amikacin, and ofloxacin were present in the drug regimen of all patients. Average duration of the treatment was 18.5 months (range, 7-36). Over 76% of the patients responded to the treatment (negative smear and culture). Cure and probable cure were documented in seven (41.2%) and four (23.5%) of the patients, respectively. No failure in the treatment occurred when cycloserine was present in the treatment regimen. Conclusion: A majority of the MDR-TB patients in Iran can be cured with the use of appropriate treatment regimens. An even greater success could be achieved by providing more second-line drugs.

AB - Setting: Masih Daneshvari Hospital, Tehran, Iran, 2000-2002. Objective: To evaluate the effectiveness of multiple drug-resistant tuberculosis (MDR-TB) treatment for the first time in Iran. Design: All cases of MDR-TB with complete follow-up data were recruited and results of their treatments were evaluated. Results: MDR-TB treatment was initiated with 5.23 drugs, on average. Isoniazid, amikacin, and ofloxacin were present in the drug regimen of all patients. Average duration of the treatment was 18.5 months (range, 7-36). Over 76% of the patients responded to the treatment (negative smear and culture). Cure and probable cure were documented in seven (41.2%) and four (23.5%) of the patients, respectively. No failure in the treatment occurred when cycloserine was present in the treatment regimen. Conclusion: A majority of the MDR-TB patients in Iran can be cured with the use of appropriate treatment regimens. An even greater success could be achieved by providing more second-line drugs.

KW - Iran

KW - Multiple drug-resistant tuberculosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=26944459230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944459230&partnerID=8YFLogxK

U2 - 10.1016/j.ijid.2004.09.012

DO - 10.1016/j.ijid.2004.09.012

M3 - Article

VL - 9

SP - 317

EP - 322

JO - International Journal of Infectious Diseases

JF - International Journal of Infectious Diseases

SN - 1201-9712

IS - 6

ER -